Fibroblast growth factor 21 is associated with widening QRS complex and prolonged corrected QT interval in patients with stable angina

Wei-Chin Hung1,2, Teng-Hung Yu1,2, Chao-Ping Wang1,3, Chia-Chang Hsu4,5, Yung-Chuan Lu3,6, Ching-Ting Wei3,7,8,9, Fu-Mei Chung1, Yau-Jiunn Lee10, Cheng-Ching Wu1,2*† and Wei-Hua Tang11,12*†

Abstract

Background: Fibroblast growth factor 21 (FGF21) is produced by cardiac cells, may acts in an autocrine manner, and was suggested to has a cardioprotective role in atherosclerosis. Wide QRS complex and heart rate-corrected QT interval (QTc interval) prolongation are associated to dangerous ventricular arrhythmias and cardiovascular disease mortality. Yet, the role of FGF21 in cardiac arrhythmia has never been studied. The aim of the study was to investigate the relationship between plasma FGF21 and the QRS duration and QTc interval in patients with stable angina.

Methods: Three hundred twenty-one consecutive stable angina patients were investigated. Plasma FGF21 was measured through ELISA, and each subject underwent 12-lead electrocardiography.

Results: FGF21 plasma levels were positively associated with the QRS duration ($\beta = 0.190$, $P = 0.001$) and QTc interval ($\beta = 0.277$, $P < 0.0001$). With increasing FGF21 tertiles, the patients had higher frequencies of wide QRS complex and prolonged QTc interval. After adjusting for patients' anthropometric parameters, the corresponding odd ratios (ORs) for wide QRS complex of the medium and high of FGF21 versus the low of FGF21 were 1.39 (95% CI 0.51–3.90) and 4.41 (95% CI 1.84–11.59), respectively, and $p$ for trend was 0.001. Furthermore, multiple logistic regression analysis also showed the corresponding odd ratios (ORs) for prolonged QTc interval of the medium and high of FGF21 versus the low of FGF21 were 1.02 (95% CI 0.53–1.78) and 1.93 (95% CI 1.04–3.60) respectively with the $p$ for trend of 0.037. In addition, age- and sex-adjusted FGF21 levels were positively associated with fasting glucose, HbA1c, creatinine, and adiponectin, but negatively associated with albumin, and the estimated glomerular filtration rate.

Conclusions: This study indicates that plasma FGF21 is associated with wide QRS complex and prolonged corrected QT interval in stable angina patients, further study is required to investigate the role of plasma FGF21 for the underlying pathogenesis.

*Correspondence: maxvic24@gmail.com; africapaul12@yahoo.com

1 Division of Cardiology, Department of Internal Medicine, E-Da Hospital, No. 1, Yi-Da Rd., Jiau-Shu Village, Yan-Chao Township, Kaohsiung 82445, Taiwan
11 Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Yuli Branch, No. 91, Xinxing St., Yuli Township, Hualien County 981002, Taiwan

Full list of author information is available at the end of the article
**Background**

The mortality and morbidity of coronary artery disease (CAD) has been decreased after the advance and universal application of either medical and aggressive intravascular intervention therapy of CAD in past decades. Unfortunately, sudden cardiac death still common and difficult to predict in these patients especially in the patient with stable angina who are relative stationary in disease progression [1]. In previous study, the risk factors of sudden death in patients with stable angina mainly focus on the comorbidities of CAD with obesity, peripheral artery disease, left ventricular ejection fraction, low-density lipoprotein cholesterol (LDL-C) levels, alcohol consumption and certain electrocardiographic abnormalities [1, 2]. In 56 years longitudinal, 3983 originally healthy young men prospective study, small electrocardiographic change such as non-specific T wave or ST/T changes were noted to be associated with high short-term risk even sustained excess risk over long term risk for sudden cardiac death [3]. However, the cause of these electrocardiographic abnormalities in patients with stable angina could not be totally explained.

Widening QRS complex greater than 120 ms without bundle branch block (BBB), is related to the slower spread of ventricular depolarization due to reliance on slower muscle-to-muscle spread of depolarization and/or disease of the His-Purkinje network. Recently, wide QRS complex has been proved to have association with an increased risk of malignant ventricular arrhythmia and adverse cardiac events [4]. The QT interval is defined as the duration from the beginning of the Q wave to the end of the T wave. It represents the start of ventricular depolarization to the end of ventricular repolarization and the prolonged corrected QT (QTc) interval is associated with an increased risk of malignant ventricular arrhythmias [5] and sudden death [6]. In addition, recent study showed both of the wide QRS complex and QTc interval prolongation are frequently found in patients with reduced left ventricular ejection fraction and cardiovascular disease with relatively poor prognosis [7, 8].

FGF21 is a previously discovered as a cardiomyokine that regulates lipid and glucose metabolism [9–11]. It is predominantly produced in the liver, and was initially identified as a hepatic endocrine factor that modulates lipid metabolism [12] and promotes thermogenic activity. FGF21 binds to β-Klotho and FGF receptor (FGFR) [13], regulate insulin sensitivity and promote glucose uptake in adipocytes [14, 15]. Recent study showed cardiac FGF21 secretion could be stimulated in response to cardiac stresses although its secretion is lower than the hepatic FGF21 origin [16]. Furthermore, FGF21 could inhibit ischemic arrhythmias by targeting the miR-143/EGR1 axis [17]. Besides, deletion of FGF21 has been shown in severe myocardial damage [16, 18], and the administration of FGF21 has been proved to prevent ventricular hypertrophy [16] and adverse cardiac remodeling after myocardial infarction (MI) mice model [19]. In contrast, clinical study showed different effects of FGF21. Chou et al. suggested that FGF21 involved in the diastolic heart failure pathophysiology [20] and Shen et al. also reported that among the CAD patients with higher serum level of FGF21, there is a higher incidence of nonfatal myocardial infarction, hospitalization, cardiac death and major adverse cardiovascular events (MACEs) [21, 22]. The effect of FGF21 to cardiovascular diseases is still unclear. In addition, until now, there are few clinical studies investigate the association between FGF21 and cardiac electrical activity in humans. Therefore, here we designed this study to investigate the relationship between FGF21 level and QRS duration and QTc interval in patients with stable angina, in the aim to evaluate the role of FGF21 in these electrocardiographic abnormalities and propose the possible effect of FGF21 to the patient future adverse cardiac events.

**Material and methods**

**Study design and participants**

There are 321 consecutive consenting patients who underwent angiography for the first time with a clinical diagnosis of stable angina included in this study. The study was taken placed in the cardiovascular department Taiwan E-Da Hospital between January 2007 and December 2016. The inclusion criteria were as follows: (1) stable angina pectoris was defined as effort-related chest tightness without evidence of recent deterioration or rest pain in the previous 6 months as previously described [23, 24]; (2) A successful percutaneous coronary intervention was defined as final angiographic residual stenosis <30%, without occlusion >1 mm coronary branch or flow-limiting dissection and with the resulting Thrombolysis in Myocardial Infarction grade 3, by quantitative coronary angiography [25]. Patients with following criteria were excluded in our study: (1) a recent inflammatory diseases (such as sepsis or infection), liver diseases, collagen diseases, malignancy or steroid use; (2) a history of psychosis with and without psychotropics; (3) history of myocardial infarction, heart valve disease, and heart surgery; (4) EKG with BBB pattern, fibrillation or flutter, ...
and atrioventricular blocks; (5) recent use of medications which has prolong QT interval effect, such as class I anti-arrhythmic (e.g. quinidine, mexiletine, etc.), class III anti-arrhythmics (e.g. amiodarone, vernakalant, etc.), certain psychotropic drug, certain microcrystal and antimalarial drugs; (6) electrolytes imbalance.

**Baseline data collection**
A detailed interview was conducted with each patient about their demographic characteristics, as well as their medical and personal history before the coronary angiography examination. Three smoking status was classified: never having smoked, former smoker (cessed smoking for at least 1 year), or current smoker. Former and current smokers were analyzed as one group in our study. Patient’s blood pressure was measured in a sitting position, after rested for 5 min, by a trained assistant, with a digital automatic blood pressure monitor (model HEM-907; Omron, Omron, Japan). Body height and body weight were measured to the nearest 0.1 cm and 0.1 kg respectively using an electronic scale with participants wearing a hospital gown. Waist and hip circumferences were measured at the narrowest point between the lowest rib and the uppermost lateral border of the right iliac crest to the nearest 0.1 cm. The hips were measured at the widest point. Body mass index (BMI) was estimated by dividing the body weight in kilograms by the square of the body height in meters by definition.

**Laboratory measurements**
Peripheral blood samples were taken after the subject had fasted for 8 h and before the coronary angiography. Complete blood cell counts, general biochemical measurement (including serum creatinine, electrolytes, uric acid, albumin, glucose, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and lipid profiles (total cholesterol, plasma triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)) were measured in all patients using standard commercial methods on a parallel, multi-channel analyzer (Hitachi 7170A, Tokyo, Japan) according to the International Federation of Clinical Chemistry methods. High performance liquid chromatography was used to measure Hemoglobin A1c (HbA1c). The concentration of plasma FGF21 was measured by enzyme-linked immunosorbent assay (ELISA) kits (Cloud-Clone Corp., Katy, USA). The dilution and standard curves were parallel. The intra- and inter-assay coefficients of variation for the assay were <10% (n = 3) and <12% (n = 3). In addition, ELISA was also used to measure high sensitivity C-reactive protein (hs-CRP) and adiponectin levels. Full details of how the bloodwork was analysed are included in the Additional file 1 [26].

**Definitions**
Type 2 diabetes was defined according to the World Health Organization criteria as a history of type 2 diabetes and/or the subject receiving anti-diabetics medical therapy [27]. Hypertension was defined as a resting systolic/diastolic blood pressure (SBP/DBP) of ≥140 mmHg/≥90 mmHg, or recent use of antihypertensive drugs. Hyperlipidemia was defined as elevated triglycerides (≥150 mg/dl), and/or low HDL-C (<35 mg/dl in men or <39 mg/dl in women), and/or elevated total cholesterol (≥200 mg/dl), and/or elevated LDL-C (≥130 mg/dl), or recent receiving treatment for a lipid disorder according to NCEP ATP III [28]. Left ventricular mass was calculated using a two-dimensional method and indexed to the body surface area. Left ventricular hypertrophy (LVH) was defined as a left ventricular mass index of >131 g/m² for men and >100 g/m² for women [29]. Furthermore, estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation within 3–6 months of admission [30]. In addition, we recorded the occurrence of MACEs after the patients were discharged from the hospital. MACEs were defined as all-cause mortality, cardiovascular-related re-hospitalization (including heart failure, non-fatal reinfarction, uncontrolled angina) or repeated percutaneous coronary interventions/coronary artery bypass grafting.

**Angiographic definitions**
Before performing coronary angiography, noninvasive stressing test such as treadmill exercise test or myocardial perfusion scintigraphy was performed to the patients at our cardiovascular outpatient department to evaluate the possibility of CAD and indication of coronary angiography. If there was a positive result, further coronary angiography was suggested and underwent if patient agreed. Coronary angiograms were performed according to standard techniques. The coronary artery stenosis severity was assessed using quantitative angiography. Quantitative coronary angiographic and angiograms analyses were evaluated by at least two experienced interventional cardiologists who were blinded to the patient’s clinical history and information. Number of diseased coronary vessels and Gensini Score were determined and full information on the scoring systems are detailed in the Additional file 1 [31].

**Electrocardiography, QT and QTc interval measurements**
The QT interval and QRS duration were manually measured by 2 cardiologists who were blinded to the study aims. A twelve-lead ECG was performed using standardized protocol at baseline at supine position after 15 min
rest during the patient admission physical examination. Standard intervals (heart rate, PR, QRS, and QT) and amplitudes (R, S, and T waves) were analyzed using standard protocols as detailed in the Additional file 1 [32–34]. The QT interval was measured from the beginning of the QRS complex to the end of the T wave in the electrocardiogram. Details of the QTc measurement please refer to the Additional file 1 [35, 36]. Prolonged QTc was defined as in men $\geq 451$ ms or women $\geq 471$ ms [37]. Abnormal wide QRS complex was defined as a QRS duration $\geq 120$ ms, but exclude those typical BBB pattern (right BBB defined as QRS duration $\geq 120$ ms with large R'-wave in V1/V2 with a broad deep S-wave in V5/V6, left BBB defined as QRS duration $\geq 120$ ms with deep broad S-wave in V1/V2 and broad clumsy R-wave in V5/V6).

### Statistical analysis

Normally distributed continuous variables are presented in mean± standard deviation (SD), and non-normally distributed continuous variables are presented in median (interquartile range (IQR)). Data normality was assessed by Kolmogorov-Smirnov test. Before statistical tests were performed, the serum levels of TGs, AST, ALT, creatinine, hs-CRP, adiponectin, and FGF21 were logarithmically transformed to achieve a normal distribution. One-way ANOVA for variables of normal distribution followed by the Tukey pairwise comparison was used to compare the differences in continuous variables between the FGF21 tertiles. Categorical variables are presented in frequencies with percentages and the inter-group comparisons were tested using chi-square test.

We further divided the distribution of FGF21 into tertile and estimate the odds ratios (ORs) of wide QRS complex and prolonged QTc interval using logistic regression models. In the analysis, we use the lowest tertile as the reference category. Multivariate adjusted ORs are presented with 95% confidence interval (CI). The correlations and independence between plasma FGF21 levels and the values of other parameters were examined by Pearson’s correlation coefficient and multiple linear regression analyses. All tests were two-tailed. A $p$-value $<0.05$ was considered to be statistically significant. All data were analyzed using JMP version 7.0 for Windows (SAS Institute, Cary, NC, USA).

### Results

#### Main characteristics

There are 321 patients enrolled in this study. 75% (241) of the participants were male with a mean age of 69.0 years (SD, 12.1 years). The mean QTc interval and QRS duration of all participants were 447 ms and 98 ms (SD, 41 ms and 21 ms). The plasma FGF21 levels were significantly higher in the patients with wide QRS complex than in those normal QRS complex [114.9 pg/mL (interquartile range, 41.8 pg/mL to 167.5 pg/mL) vs. 38.8 pg/mL (interquartile range, 19.4 pg/mL to 79.5 pg/mL), Fig. 1A]. Furthermore, the plasma levels of FGF21 were significantly higher in the patients with prolonged QTc interval [61.0 pg/mL (interquartile range, 27.5 pg/mL to 140.1 pg/mL) with prolonged QTc vs. 37.4 pg/mL (interquartile range, 20.1 pg/mL to 73.5 pg/mL) with normal QTc, Fig. 1B]. Table 1 shows the clinical characteristics of studied participants stratified by FGF21. The mean FGF21 level

![Figure 1](https://example.com/figure1)

**Fig. 1** Patients with wide QRS complex had significantly higher fibroblast growth factor 21 (FGF21) compared to patients with normal QRS complex (A). Patients with prolonged QTc interval had significantly higher FGF21 compared to patients with normal QTc interval (B). The bottom of the box plots indicates the 25th percentile and the top indicates the 75th percentile. The middle line of the box indicates the median. The lower and upper ends of the whiskers indicate the minimum and maximum observations below the upper fence (1.5 interquartile range above the 75th percentile), respectively.
was 85.2 pg/mL, and the median plasma FGF21 level was 42.4 pg/mL (interquartile range, 21.1 pg/mL to 100.2 pg/mL). All the subjects were divided according to tertiles of FGF21 as follows: low FGF21 \((\leq 28.5 \text{ pg/mL})\), \(n = 108\); medium FGF21 \((28.6 \text{ pg/mL to 65.8 pg/mL})\), \(n = 106\); and high FGF21 \((> 65.8 \text{ pg/mL})\), \(n = 107\). The high FGF21 patients were older and had higher rates of LVH, all-cause mortality, wide QRS complex, and prolonged QTc. Furthermore, these patients also had higher levels of waist-to-hip ratio, heart rate, and QRS duration than those with the low FGF21 group.

Moreover, Longer QTc interval was also noted in the high FGF21 group than the medium and low FGF21 groups. In addition, the patients in the high FGF21 group also had lower rates of hyperlipidemia, current smoker, and statin medication, as well as lower left ventricular ejection fraction (LVEF) compared with those who had the low FGF21 group.

### Biochemical characteristics
In Table 2, with the increase of FGF21 tertile, there were significant decreases of eGFR, hemoglobin, and albumin.

### Table 1  Main characteristics according to tertiles of fibroblast growth factor 21

| Parameter                                      | Low FGF21 \((\leq 28.5 \text{ pg/mL})\) | Medium FGF21 \((28.6 – 65.8 \text{ pg/mL})\) | High FGF21 \((> 65.8 \text{ pg/mL})\) | \(P\)-value |
|------------------------------------------------|----------------------------------------|---------------------------------------------|----------------------------------------|-------------|
| Number                                         | 108                                    | 106                                         | 107                                    |             |
| Sex (male/female)                              | 82/26                                  | 84/22                                       | 75/32                                  | 0.294       |
| Age (years)                                    | 66.5 ± 12.0                           | 68.0 ± 11.8                                 | 72.5 ± 11.6                           | 0.001       |
| Hypertension (n, %)                            | 76(70.4)                               | 78(73.6)                                    | 80(74.8)                               | 0.754       |
| Hyperlipidemia (n, %)                          | 71(65.7)                               | 75(70.8)                                    | 56(52.3)                               | 0.016       |
| Diabetes mellitus (n, %)                       | 37(34.3)                               | 50(47.2)                                    | 51(47.7)                               | 0.079       |
| Left ventricular hypertrophy (n, %)            | 50(46.3)                               | 52(49.1)                                    | 72(67.3)                               | 0.032       |
| MACEs (n, %)                                   | 45(41.7)                               | 59(55.7)                                    | 49(45.8)                               | 0.109       |
| All-cause Mortality (n, %)                     | 8(7.4)                                 | 14(13.2)                                    | 21(19.6)                               | 0.031       |
| Current smoker (n, %)                          | 46(42.6)                               | 50(47.2)                                    | 33(30.8)                               | 0.043       |
| Body mass index (kg/m\(^2\))                  | 25.7 ± 3.9                             | 26.1 ± 3.6                                  | 24.7 ± 4.5                             | 0.044       |
| Waist-to-hip ratio                             | 0.93 ± 0.07                            | 0.94 ± 0.06                                 | 0.97 ± 0.12                            | 0.010       |
| Systolic BP (mmHg)                             | 130 ± 22                               | 131 ± 22                                    | 130 ± 26                               | 0.926       |
| Diastolic BP (mmHg)                            | 76 ± 14                                | 77 ± 12                                     | 77 ± 15                                | 0.992       |
| LVEF (%)                                       | 60.8 ± 15.1                            | 58.8 ± 15.5                                 | 55.5 ± 16.0                            | 0.045       |
| Electrocardiography parameters                |                                        |                                             |                                        |             |
| Heart rate (bpm)                               | 74.0 ± 17.6                            | 77.6 ± 20.0                                 | 83.1 ± 20.8                            | 0.003       |
| PR interval (ms)                               | 167 ± 30.4                             | 169 ± 26.5                                  | 172 ± 39.7                             | 0.540       |
| QRS duration (ms)                              | 93.7 ± 15.8                            | 98.4 ± 22.1                                 | 103.1 ± 22.2                           | 0.004       |
| QT interval (ms)                               | 394.7 ± 46.0                           | 399.3 ± 44.9                                | 401.1 ± 57.9                           | 0.626       |
| QTc interval (ms)                              | 434.2 ± 35.6                           | 444.5 ± 35.6                                | 461.9 ± 45.3                           | < 0.0001    |
| Wide QRS complex† (n, %)                       | 8(7.4)                                 | 12(11.3)                                    | 33(30.8)                               | < 0.0001    |
| Prolonged QTc interval‡ (n, %)                 | 30(27.8)                               | 32(30.2)                                    | 51(47.7)                               | 0.004       |
| Medication (n, %)                              |                                        |                                             |                                        |             |
| Anti-arrhythmic medication                     | 10(9.3)                                | 8(7.6)                                      | 10(9.4)                                | 0.871       |
| Beta-blockers                                  | 58(53.7)                               | 57(53.8)                                    | 49(45.8)                               | 0.406       |
| Diuretics                                      | 31(28.7)                               | 33(31.1)                                    | 31(29.0)                               | 0.913       |
| Statins                                        | 66(61.1)                               | 59(55.7)                                    | 45(42.1)                               | 0.016       |
| Number of diseased vessels (%)                 |                                        |                                             |                                        |             |
| Single-vessel disease                          | 35(32.4)                               | 33(31.1)                                    | 28(26.2)                               | 0.574       |
| Two-vessel disease                             | 24(22.4)                               | 36(34.0)                                    | 39(36.5)                               | 0.054       |
| Three-vessel disease                           | 49(45.4)                               | 37(34.9)                                    | 40(37.4)                               | 0.260       |

Data are expressed as the mean ± SD, number (percentage), or median (interquartile range). FGF fibroblast growth factor; QTc corrected QT; LVEF left ventricular ejection fraction; MACEs major adverse cardiovascular events

† Wide QRS complex was defined as a QRS duration > 120 ms
‡ Prolonged QTc was defined as a men ≥ 451 ms or women ≥ 471 ms
concentrations. In the other hand, the increasing of FGF21 tertile also found in significant increases of fasting glucose, HbA1c, blood urine nitrogen (BUN), creatinine, hs-CRP, and adiponectin concentrations.

### Association of the FGF21 for the Wide QRS Complex and Prolonged QTc Interval

Table 3 shows results the ORs of the wide QRS complex and prolonged QTc interval estimation according to the FGF21 tertiles. Compared with subjects with low of FGF21, the ORs of wide QRS complex for medium

---

**Table 2** Biochemical characteristics according to tertiles of fibroblast growth factor 21

| Parameter                  | Low FGF21 ≤ 28.5 pg/mL | Medium FGF21 = 28.6–65.8 pg/mL | High FGF21 > 65.8 pg/mL | P-value |
|----------------------------|------------------------|---------------------------------|-------------------------|---------|
| Number                     | 108                    | 106                             | 107                     |         |
| Total-cholesterol (mg/dl)  | 171.0 ± 44.5           | 177.1 ± 45.6                    | 171.3 ± 46.1            | 0.548   |
| Triglycerides (mg/dl)      | 96.5(70.3–154.8)       | 120.0(75.5–174.0)               | 127.0(87.0–183.0)       | 0.104   |
| HDL-cholesterol (mg/dl)    | 40.4 ± 10.5            | 38.4 ± 13.2                     | 39.0 ± 12.0             | 0.467   |
| LDL-cholesterol (mg/dl)    | 103.6 ± 36.5           | 108.5 ± 38.9                    | 97.6 ± 38.4             | 0.116   |
| AST (U/L)                  | 32.0(25.0–46.5)        | 32.0(23.0–43.3)                 | 35.0(25.0–70.0)         | 0.060   |
| ALT (U/L)                  | 30.0(19.0–43.8)        | 31.0(19.0–46.8)                 | 27.0(17.0–52.0)         | 0.281   |
| Fasting glucose (mg/dl)    | 138.3 ± 67.6           | 151.3 ± 81.3                    | 170.7 ± 94.6            | 0.016   |
| HbA1c (%)                  | 6.6 ± 1.5              | 7.1 ± 1.8                       | 7.3 ± 1.8               | 0.027   |
| Uric acid (mg/dl)          | 7.3 ± 6.4              | 7.2 ± 2.4                       | 7.2 ± 2.5               | 0.988   |
| BUN (mg/dl)                | 19.9 ± 7.1             | 23.8 ± 16.5                     | 32.0 ± 20.9             | <0.0001 |
| Creatinine (mg/dl)         | 1.1(1.1–1.4)           | 1.3(1.1–1.6)                    | 1.7(1.3–3.6)            | <0.0001 |
| Estimated GFR (ml/min/1.73m²) | 65.3 ± 18.1        | 56.6 ± 22.0                     | 39.2 ± 24.3             | <0.0001 |
| Sodium (meq/l)             | 138.9 ± 36             | 138.8 ± 43                      | 138.3 ± 43              | 0.480   |
| Potassium (meq/l)          | 3.8 ± 0.4              | 3.8 ± 0.8                       | 4.0 ± 0.7               | 0.158   |
| Calcium (mg/dl)            | 8.7 ± 0.5              | 8.7 ± 1.0                       | 8.8 ± 1.0               | 0.576   |
| Hemoglobin (g/dl)          | 13.6 ± 1.9             | 13.4 ± 2.2                      | 12.2 ± 2.4              | <0.0001 |
| Albumin (g/dl)             | 4.0 ± 0.6              | 3.8 ± 0.5                       | 3.7 ± 0.5               | 0.0004  |
| Hs-CRP (mg/l)              | 1.5(0.7–5.1)           | 3.1(1.2–10.0)                   | 4.3(1.5–15.0)           | 0.044   |
| Adiponectin (µg/ml)        | 4.0(1.8–10.7)          | 4.2(1.6–6.5)                    | 6.9(3.7–13.4)           | 0.0002  |

Data are expressed as the mean ± SD, number (percentage), or median (interquartile range). FGF fibroblast growth factor; HDL high-density lipoprotein; LDL low-density lipoprotein; AST aspartate aminotransferase; ALT alanine aminotransferase; BUN blood urea nitrogen; GFR glomerular filtration rate; Hs-CRP high-sensitivity C-reactive protein

---

**Table 3** ORs for wide QRS complex and prolonged QTc interval according to fibroblast growth factor 21 tertiles (95% CI)

| Factor                  | Low FGF21 ≤ 28.5 pg/mL | Medium FGF21 = 28.6–65.8 pg/mL | High FGF21 > 65.8 pg/mL | P for trend |
|-------------------------|------------------------|---------------------------------|-------------------------|-------------|
| Number                  | 108                    | 106                             | 107                     |             |
| Wide QRS complex        |                        |                                 |                         |             |
| Model 1                 | 1.00                   | 1.60 (0.63–4.24)                | 5.57 (2.54–13.61)       | <0.0001     |
| Model 2                 | 1.00                   | 1.54 (0.61–4.10)                | 5.16 (2.32–12.74)       | <0.0001     |
| Model 3                 | 1.00                   | 1.54 (0.59–4.19)                | 4.92 (2.18–12.27)       | <0.0001     |
| Model 4                 | 1.00                   | 1.39 (0.51–3.90)                | 4.41 (1.84–11.59)       | 0.001       |
| Prolonged QTc interval  |                        |                                 |                         |             |
| Model 1                 | 1.00                   | 1.12 (0.62–2.04)                | 2.37 (1.35–4.21)        | 0.003       |
| Model 2                 | 1.00                   | 1.09 (0.60–1.98)                | 2.08 (1.17–3.74)        | 0.013       |
| Model 3                 | 1.00                   | 1.05 (0.57–1.95)                | 2.14 (1.19–3.89)        | 0.011       |
| Model 4                 | 1.00                   | 1.02 (0.53–1.78)                | 1.93 (1.04–3.60)        | 0.037       |

Model 1 unadjusted model, Model 2 adjusted for age and sex, Model 3 additionally adjusted for body mass index, total-cholesterol, potassium, and smoking, Model 4 additionally adjusted for diabetes mellitus, hypertension, chronic kidney disease, statins medication. FGF fibroblast growth factor
high of FGF21 were 1.60 (95% CI 0.63–4.24) and 5.57 (95% CI 2.54–13.61) respectively. Using multiple logistic regression with adjustment, the corresponding ORs of the wide QRS complex for medium and high of FGF21 versus low of FGF21 still high (1.39 (95% CI 0.51–3.90) and 4.41 (95% CI 1.84–11.59) respectively).

Similarly, compared to the participants with low of FGF21, the ORs of prolonged QTc interval for medium and high of FGF21 were 1.12 (95% CI 0.62–2.04) and 2.37 (95% CI 1.35–4.21). After adjustment in the multiple logistic regression, the corresponding ORs of the prolonged QTc interval for medium and high of FGF21 versus low of FGF21 remained 1.02 (95% CI 0.53–1.78) and 1.93 (95% CI 1.04–3.60).

**Association between plasma FGF21 levels and clinical laboratory data**

Pearson's correlation analysis showed the plasma FGF21 levels were positively correlated with age, heart rate, QRS duration, QTc interval, fasting glucose, HbA1c, BUN, creatinine, hs-CRP, and adiponectin. However, they were negatively correlated with LVEF, BMI, current smoking, LDL-C, albumin, and eGFR (Table 4). Furthermore, age- and sex-adjusted FGF21 levels were significantly positively associated with heart rate, QRS duration, QTc interval, fasting glucose, HbA1c, BUN, creatinine, and adiponectin. In contrast, they were significantly negatively associated with current smoking, LDL-C, albumin, and eGFR. Moreover, age and sex-adjusted FGF21 levels were not significantly correlated with PR interval, QT interval, LVEF, left ventricular mass index, SBP, DBP, BMI, waist circumference, total cholesterol, TGs, HDL-C, and hs-CRP in our analysis (Table 4).

**Type 2 diabetes mellitus (T2DM) affects plasma levels of FGF21**

In the patients with T2DM, the levels of plasma FGF21 were significantly higher than in those without T2DM [46.6 pg/mL (interquartile range, 28.2 pg/mL to 125.1 pg/mL) vs. 38.1 pg/mL (interquartile range, 17.6 pg/mL to 84.1 pg/mL), p = 0.035; Fig. 2]. Furthermore, the patients with a wide QRS complex and T2DM had higher levels of FGF21 than those with normal QRS complex with and without T2DM, but not those with wide QRS complex without T2DM (Fig. 3A). Moreover, the T2DM patients with a prolonged QTc interval had higher levels of FGF21 than those with normal QTc interval with or without T2DM, but not those with prolonged QTc interval without T2DM (Fig. 3B).

**Table 4 Association between plasma fibroblast growth factor 21 levels and clinical laboratory data**

| Characteristic                  | Model 1 | P-value | Model 2 | P-value |
|--------------------------------|---------|---------|---------|---------|
|                                | r       |         | β       |         |
| Age                            | 0.174   | 0.002   | –       | –       |
| Male sex                       | –0.069  | 0.217   | –       | –       |
| Heart rate                     | 0.184   | 0.001   | 0.155   | 0.006   |
| PR interval                    | 0.086   | 0.150   | 0.074   | 0.209   |
| QRS duration                   | 0.191   | 0.001   | 0.180   | 0.001   |
| QT interval                    | 0.038   | 0.500   | 0.024   | 0.667   |
| Corrected QT interval          | 0.277   | <0.0001 | 0.247   | <0.0001 |
| LVEF                           | –0.127  | 0.035   | –0.094  | 0.125   |
| Left ventricular mass index    | 0.126   | 0.089   | 0.130   | 0.083   |
| Systolic blood pressure        | –0.023  | 0.681   | –0.041  | 0.472   |
| Diastolic blood pressure       | –0.012  | 0.839   | –0.009  | 0.873   |
| Body mass index                | –0.125  | 0.026   | –0.092  | 0.115   |
| Waist circumference            | –0.040  | 0.551   | –0.045  | 0.513   |
| Current smoking                | –0.176  | 0.002   | –0.167  | 0.007   |
| Total-cholesterol              | –0.070  | 0.217   | –0.048  | 0.398   |
| Triglycerides                  | 0.058   | 0.299   | 0.112   | 0.052   |
| HDL-cholesterol                | –0.041  | 0.462   | –0.050  | 0.368   |
| LDL-cholesterol                | –0.168  | 0.003   | –0.155  | 0.006   |
| Fasting glucose                | 0.180   | 0.001   | 0.170   | 0.002   |
| HbA1c                          | 0.149   | 0.016   | 0.152   | 0.014   |
| Albumin                        | –0.239  | <0.0001 | –0.204  | 0.001   |
| Blood urea nitrogen            | 0.344   | <0.0001 | 0.331   | <0.0001 |
| Creatinine                     | 0.526   | <0.0001 | 0.522   | <0.0001 |
| Estimated GFR                  | –0.483  | <0.0001 | –0.566  | <0.0001 |
| Hs-CRP                         | 0.130   | 0.023   | 0.103   | 0.074   |
| Adiponectin                    | 0.256   | <0.0001 | 0.222   | <0.0001 |

Model 1: Pearson correlation coefficient. Model 2: Regression coefficient adjusted for age and sex. LVEF left ventricular ejection fraction; LDL high-density lipoprotein; LDL low-density lipoprotein; GFR glomerular filtration rate; Hs-CRP high-sensitivity C-reactive protein

**Discussion**

Among 321 stable angina patients in our study, there are 16% of the patients have wide QRS without BBB and near one third of them have a prolonged QTc by definition. We found the plasma FGF21 level was increased in patients with a wide QRS complex and prolonged QTc interval with and without adjusted model. From our analysis, the plasma FGF21 level was positively associated with fasting glucose, HbA1c, creatinine and adiponectin, but negatively associated with albumin and eGFR. To the best of our knowledge, this is the first study to show an association between increased plasma FGF21 level and wide QRS complex and prolonged QTc interval in human subjects.

The biological effect of FGF21 on CAD are not well understood. Literatures review showed a higher FGF21
in patient with diastolic heart failure or CAD with greater risk of MACEs [21, 22] but have a cardioprotecting and antiarrhythmic effect in animal studies [16–19]. This conflict observation is interesting. In previous animal study, FGF21 treatment reduced susceptibility to arrhythmia in infarcted mice hearts by suppressing miR-143 expression and regulate the EGR1-SCN5A/KCNJ2 pathway in MI [17]. However, some vivo experiments, FGF21 levels was found to be correlated with the dysregulated metabolic status. For examples, FGF21 resistance has been observed in in vivo experiments with DIO mice livers and white adipose tissue [38], and another report in ex vivo experiments with obese rat hearts [39]. Furthermore, FGF21 resistance has also been observed in clinical reports where the serum FGF21 level was significantly increased in patients with nonalcoholic fatty liver disease (NAFLD) [40], coronary heart disease [40, 41], metabolic syndrome [42], and T2DM [43]. While FGF21 mainly secreted by the liver which regulates insulin sensitivity and glucose homeostasis [44], FGF21 has also been identified in the heart as a paracrine signal protein [45]. In one clinical study, FGF21 is found abundantly secreted into the plasma in response to cardiac stress stimuli in patients with cardiovascular diseases [46].

QRS complex is modified by various mechanisms and clinical conditions. A wide QRS complex may be related to obesity [47], cigarette smoking [48], hypertension [47], NAFLD [49], diabetes mellitus [50], metabolic syndrome [51], heart failure [52], CKD [53], and inflammation [54]. As patient with heart diseases always has metabolic dysregulation problems, high serum FGF21 levels in these patients are reasonable. Therefore, we suggest serum FGF21 levels could be considered an indicator of adverse metabolic dysregulation but not the explanation of the cause of these abnormal cardiac function parameters findings.
Previous studies reported there is an increase of FGF21 levels in cardio-metabolic conditions such as CAD, heart failure, atrial fibrillation, MI, obesity, and diabetes mellitus [55, 56]. In recent one study regarding the influence of lifestyle to the FGF21 serum level. It showed the age, aminotransferase, gamma-glutamyl transpeptidase, smoking status, and breakfast and alcohol consumption frequency were independently associated with FGF21 levels. More interestingly, the FGF21 levels were found more profound correlated with waist circumference, SBP, and total cholesterol in the relative healthy the non-obese group [57]. These findings are consistent with our study result. With increasing FGF21 tertiles, we found our patients had a higher waist-to-hip ratio and HbA1c as well as higher prevalence of LVH and incrementally lower LVEF.

In our study, we found that the QT interval is prolonged with the increase of FGF21 levels. QT interval prolongation has been associated with diabetes, obesity, and adiposity, cardiovascular diseases which are all related to an increased FGF21 level [40]. Yilmaz et al. further suggested regional adipose tissue deposition especially epicardial fat volume may play an important role in QT interval prolongation pathogenesis [58]. As FGF21 was identified as a hepatic endocrine factor which modulates lipid metabolism, and the serum FGF21 level progressively increased with visceral fat, and associated with NAFLD [59], it is reasonable to proposed there is a possible link between FGF21 and prolonged QTc interval via the lipid metabolism happened at epicardial fatty tissue. However, like the phenomenon we found in QRS interval. FGF21 might not directly induced the prolonged QTc interval but reflect the complex underlying metabolic dysregulation and comorbidity of the patients.

In our study, we found that a high FGF21 level was significantly associated with all-cause mortality in stable angina patients which similar to previous observations. FGF21 levels were known significantly correlated with left ventricular systolic dysfunction at baseline and has a greater risk to develop MACEs and cardiac death [21, 60]. Furthermore, elevated circulating FGF21 levels also found in patients with carotid atherosclerosis [61], subclinical atherosclerosis [62], CHD [41], and acute MI [63]. All these data logically conduct the idea that high levels of serum FGF21 may be indicative for the adverse cardiovascular events following CAD. However, because of the relative short duration of follow-up and small sample size, further studies with a longer follow-up period and larger patient population are still required to confirm this finding.

Interestingly, we found that T2DM patients had significantly higher FGF21 levels compared to patients without T2DM in our study. The T2DM patients with a wide QRS complex had higher levels of FGF21 than those with normal QRS complex with and without T2DM. Moreover, the patients with a prolonged QTc interval and T2DM also had higher levels of FGF21 than those with normal QTc interval with or without T2DM. Recently, few studies have shown the early compensatory high serum level of FGF21 levels might be responsive to the occurrence and development of DM-induced cardiovascular complications [62, 64]. In addition, the deletion of FGF21 has also been proved to have the relationship with the aggravation of DM-induced cardiovascular injury in some reports [18, 65].

In our study, a higher FGF21 level was positively associated with plasma adiponectin level. Adiponectin and FGF21 both control the metabolism of lipids and carbohydrates, which is essential for the maintenance of energy homeostasis in the body and hence for survival. In one of our previous studies, plasma adiponectin levels have been proved to have the correlation with QTc interval prolongation [66]. A previous study further demonstrated adiponectin could mediates the metabolic effects of FGF21 [66]. In addition, insulin resistance, which is associated with adiponectin resistance, also found could predict a future increase in Tpeak-Tend interval which will influence QT interval in the general population [68].

Therefore, on the basis with all our findings and other reports, we hypotheses the mechanisms that may be involved the effects of an elevated FGF21 level to the electrocardiographic abnormalities we observed. First, the increase of serum FGF21 may be associated with the corresponding metabolic dysregulation. Second, in individuals with metabolic abnormalities, the FGF21 signaling pathway may be impaired, leading to FGF21 resistance. As the more severe of the underlying metabolic abnormalities, the secretion of FGF21 increased and the associated electrocardiographic abnormalities become obvious.

There were some limitations to the current study. First, the cross-sectional design of our study limits the ability to infer any causal relationships between FGF21 level and wide QRS complex and QTc prolongation and limited the robust comparisons. Further case controlled and cohort studies are required. Second, we did not determine the 24-h Holter and more complex cardiac electroactivity parameters such as heart rate variability, PR and QT interval variability in this report, further calculation should be performed in the future to evaluate relevant arrhythmias and the sympathetic and parasympathetic effect of the FGF21. Third, although the ST-T manifestation is very common in stable angina patients, we did not analyze it in our study. It is because the ST-T manifestation is relative complex. Despite of the segment duration, it always involves the amplitude and direction of the ST-T
wave. The ST-T manifestation in angina patients always affected by the timing of myocardial ischemia, the myocardial area supplied by the diseased coronary artery and also due the alternation in ventricular repolarization and cardiomyocyte electrophysiology [69, 70]. Forth, if the study population had different severity and phases of heart diseases (such as stable angina versus acute coronary syndrome or chronic ischemic heart diseases), differences in clinical scenery may have different impact on the results. To avoid selection bias, we had chosen individuals with stable angina in this study, and thus our results may not be generalizable to other populations. Fifth, we did not evaluate the genetic factor in our study, possible confounding effects cannot be excluded. Finally, the underlying mechanism how FGF21 is associated with cardiomyocyte ion channel expression and electrophysiology remains unclear, further investigations are warranted to elucidate these issues.

Conclusion
This study indicates that plasma FGF21 is associated with a wide QRS complex and prolonged corrected QT interval in patients with stable angina. However, the underlying mechanisms by which FGF21 result in prolonged QRS duration and QTc interval remain unclear and need to be investigated.

Abbreviations
CAD: Coronary artery disease; LDL-C: Low-density lipoprotein cholesterol; BBB: Bundle branch block; QTc: Corrected QT; FGFs: Fibroblast growth factors; FGFR: FGF receptor; Sirt1: Silent information regulator 1; MI: Myocardial infarction; MACES: Major adverse cardiovascular events; BMI: Body mass index; TGs: Triglycerides; HDL-C: High-density lipoprotein cholesterol; HbA1c: Hemoglobin A1c; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ELISA: Enzyme-linked immunosorbent assay; hs-CRP: High sensitivity C-reactive protein; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LVH: Left ventricular hypertrophy; eGFR: Estimated glomerular filtration rate; CKD-EPI: Chronic kidney disease epidemiology collaboration; SD: Standard deviation; IQR: Interquartile range; ORs: Odds ratios; CI: Confidence interval; BUN: Blood urea nitrogen; T2DM: Type 2 diabetes mellitus; NAFLD: Nonalcoholic fatty liver disease; LVEF: Left ventricular ejection fraction.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02868-3.

Acknowledgements
None.

Author contributions
Of the 10 authors, Dr. W.-C.H. is the first author who conceived and designed the study and interpreted the data. Drs. C.-C.W., T.-H.Y., C.-P.W., C.-C.H., Y.-C.Lu., Y.-J.L., C.-T.W., and W.-H.T contributed to drafting of the manuscript or revising it critically for important intellectual content. Drs. C.-P.W., W.-C.H., C.-C.W., and T.-H.Y. acquired data, drafted the manuscript and designed the study. Dr. F.-M.C. participated in the design of the study and performed the statistical analysis. Drs. W.-H.T. and C.-C.W. are the co-corresponding authors and contributed to the final approval of the manuscript as submitted. All authors read and approved the final version of the manuscript.

Funding
This work was supported by grants from E-Da Hospital of the Republic of China, Taiwan (contract no. EDAHI1090002, EDCHP109001, and EDAHI10001).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki, and the study protocol and informed consent procedure were approved by the Ethics Committee of E-Da Hospital (EDAIRB No. EMRP-108-111). All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all subjects involved in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Cardiology, Department of Internal Medicine, E-Da Hospital, No. 1, Yi-Da Rd., Jiau-Shu Village, Yan-Chao Township, Kaohsiung 82445, Taiwan. 2 School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan. 3 School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan. 4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, Kaohsiung 82445, Taiwan. 5 School of Chinese Medicine for Post Baccalaureate College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan. 6 Division of Endocrinology and Metabolism, Department of Internal Medicine, E-Da Hospital, Kaohsiung 82445, Taiwan. 7 Division of General Surgery, Department of Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan. 8 Department of Biomedical Engineering, I-Shou University, Kaohsiung 82445, Taiwan. 9 Department of Electrical Engineering, I-Shou University, Kaohsiung 82445, Taiwan. 10 Department of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Yuli Branch, No. 91, Xinxing St., Yuli Township, Hualien County 981002, Taiwan. 11 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.

Received: 3 July 2022   Accepted: 21 September 2022
Published online: 30 September 2022

References
1. Benchimol D, Dubroca B, Bernard V, Lavie J, Paviot B, Benchimol H, et al. Short- and long-term risk factors for sudden death in patients with stable angina. Int J Cardiol. 2000;76:147–56.
2. Narayanan K, Chugh SS. The 12-lead electrocardiogram and risk of sudden death: current utility and future prospects. Europace. 2015;17(Suppl 2):7–13.
3. Cuddy TE, Tate RB. Sudden unexpected cardiac death as a function of time since the detection of electrocardiographic and clinical risk factors in apparently healthy men: the Manitoba follow-up study, 1948 to 2004. Can J Cardiol. 2006;22:205–11.
4. Ohkubo K, Watanabe I, Okumura Y, Ashino S, Kofune M, Nagashima K, et al. Prolonged QRS duration in lead V2 and risk of life-threatening ventricular Arrhythmia in patients with Brugada syndrome. Int Heart J. 2011;52:98–102.
5. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72:238-258.
6. Passman R, Kadish A. Polymorphic ventricular tachycardia, long QT syndrome, and torsades de pointes. Med Clin North Am. 2001;85:321-41.
7. Wang NC, Maggioni AP, Kontz MA, Zannad F, Krasa HB, Burnett JC, Jr, et al. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299:2656–66.
8. Robbins J, Nelson JC, Rautaharju PM, Goldtiener JS. The association between the length of the QT interval and mortality in the cardiovascular health study. Am J Med. 2003;115:689–94.
9. Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and cardiac physiology. Front Endocrinol. 2015;6:133.
10. Zhang J, Li Y. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov Today. 2014;19:579–89.
11. Tanajak P, Chattipakorn SC, Chattipakorn N. Effects of fibroblast growth factor 21 on the heart. J Endocrinol. 2015;227:R13-30.
12. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Fibroblast growth factor 21 on the heart. J Endocrinol. 2015;227:R13‑30.
13. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, et al. FGF‑21/FGF‑21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol. 2008;215:1–7.
14. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Miccanovic R, Balgreath EJ, et al. FGF21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627–35.
15. Sarruf DA, Thaler JP, Morton GI, German I, Fischer JD, Ogimoto K, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59:1817–24.
16. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019.
17. Li J, Xu C, Liu Y, Li Y, Du S, Zhang R, et al. Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR‑143/EGFR. Basic Res Cardiol. 2020;115:9.
18. Yan X, Chen J, Zhang C, Zhou S, Zhang Z, Chen J, et al. FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J Cell Mol Med. 2015;19:1557–68.
19. Joki Y, Ohashi K, Yusa D, Shibata R, Ito M, Matsuo K, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun. 2015;459:124–30.
20. Chou RH, Huang PH, Hu CY, Chang CC, Leu HB, Huang CC, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6:33953.
21. Shen Y, Zhang X, Xu Y, Xiong Q, Lu Z, Ma X, et al. Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease. Cardiology. 2018;139:212–8.
22. Shen Y, Zhang X, Pan X, Xu Y, Xiong Q, Lu Z, et al. Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death. Cardiovasc Diabetol. 2017;16:106.
23. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, et al. Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis. 2010;211:579-83.
24. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American college of cardiology/american heart association task force on practice guidelines (Committee on management of patients with chronic stable Angina). Circulation. 1999;99:2829–48.
25. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl J Med. 1985;312:932–6.
26. Tang WH, Wang CP, Chung FM, Huang LH, Yu TH, Hung WC, et al. Uremic retention solute indoxyl sulfate level is associated with prolonged QTc interval in early CKD patients. PLoS One. 2015;10:e0119545.
27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285:2486–97.
29. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham heart study. Am J Cardiol. 1987;59:956–60.
30. Kong X, Ma Y, Chen L, Luo J, Xu Y, Li L, et al. Chinese eGFR Investigation Collaboration. Evaluation of the Chronic Kidney Disease GFR equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2013;28:641–51.
31. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
32. Friedman HH. Diagnostic electrocardiography and vectorcardiography. New York: McGraw-Hill, 1971.
33. Sokolov L, Lyon TO. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161–86.
34. Macon BJ, Wolfson JK, Ciró E, Solski J. Serum fibroblast growth factor 21 is predictive of coronary heart disease in a population of older adults. J Am Coll Cardiol. 2006;47:362–9.
35. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One. 2014;9:e87102.
36. Patel V, Adya R, Chen J, Ramanjanaey M, Bari MF, Bhudia SK, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59:781–9.
37. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362–9.
38. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. FGF21 deletion in mice: a novel genetic model for obesity. Diabetes. 2010;59:2781–9.
39. Shiraishi Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013;12:124.
40. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. Serum levels of FGF21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2010;5:e15534.
41. Lee Y, Lim S, Hong ES, Kim JH, Moon MK, Chon EJ, et al. Serum FGF21 concentration is associated with hypertiglycemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol. 2014;80:57–64.
42. Lenart-Liprška M, Matyjašek-Matuszek B, Gernand W, Nowakowski A, Solski J. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract. 2013;101:194–200.
43. Tucker B, Li H, Long X, Rye KA, Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism. 2019;101:153994.
44. Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol. 2016;4:110.
45. Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol. 2016;4:110.
46. Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol. 2016;4:110.
47. Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol. 2016;4:110.
48. Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol. 2016;4:110.
nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: a cross-sectional study. PLoS One. 2020;15:e023760.

50. Grisanti LA. Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. Front Physiol. 2018;9:1169.

51. Elfors TW, de Mutsert R, Lamb HJ, Maan AC, Macfarlane PW, Willems van Dijk K, et al. Association of metabolic syndrome and electrocardiographic markers of subclinical cardiovascular disease. Diabetol Metab Syndr. 2017. https://doi.org/10.1186/s13098-017-0238-9.

52. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol. 2003;46:2183–92.

53. Thomsen MB, Nielsen MS, Aarup A, Bisgaard LS, Pedersen TX. Uremia increases QRS duration after β-adrenergic stimulation in mice. Physiol Rep. 2018;6:e13720.

54. Cetin M, Kocaman SA, Canga A, Durakoglugil ME, Erdogan T, Satiroglu O, et al. The independent relationship between systemic inflammation and fragmented QRS complexes in patients with stable angina pectoris. Kardiol Pol. 2012;70:666–75.

55. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol. 2013;78:489–96.

56. Nakanishi K, Ishibashi C, Ide S, Yamamoto R, Nishida M, Nagatomo I, et al. Serum FGF21 levels are altered by various factors including lifestyle behaviors in male subjects. Sci Rep. 2011;11:22632.

57. Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation. 2015;131:1861–71.

58. Yılmaz AS, Çinier G, Çırakoğlu ÖF, Çetin M. Epicardial adipose tissue pre-treatment with high glucose induces adiponectin while reducing the aorta in type 1 diabetic mice. Cardiovasc Diabetol. 2015;14:77.

59. Liu WY, Huang S, Shi KQ, Zhao CC, Chen LL, Braddock M, et al. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin Ther Targets. 2014;18:1305–13.

60. Luo Y, Lu W. Serum levels of FGF21 and prediction of cardiovascular events. Cardiology. 2018;139:219–21.

61. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Artheroscler Thromb Vasc Biol. 2013;33:2454–9.

62. Xiao Y, Lu L, Xu A, Zhou P, Long Z, Tu Y, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:72.

63. Zhang W, Chu S, Ding W, Wang F. Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One. 2015;10:e0129791.

64. An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract. 2012;96:196–203.

65. Yan X, Chen J, Zhang C, Zeng J, Zhou S, Zhang Z, et al. Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice. Cardiovasc Diabetol. 2015;14:77.

66. Goetz R. Metabolism: Adiponectin—a mediator of specific metabolic actions of FGF21. Nat Rev Endocrinol. 2013;9:506–8.

67. Wu CC, Chang CS, Hsu CC, Wang CP, Tsai IT, Lu YC, et al. Elevated plasma adiponectin levels are associated with abnormal corrected QT interval in patients with stable angina. Int Heart J. 2020;61:29–38.

68. Matsumoto T, Ohnishi H, Sato T, Miki T, Akasaka H, Hanawa N, et al. Insulin resistance is associated with longitudinal changes of cardiac repolarization heterogeneity in apparently healthy subjects. Cardiol Ther. 2019;8:239–51.

69. Correa R, Arini PD, Correa LS, Valentiniuzzi M, Laciar E. Novel technique for ST-T interval characterization in patients with acute myocardial ischemia. Comput Biol Med. 2014;40:49–55.

70. Tikkkanen JT, Kentta T, Porthan K, Huikuri HV, Junttila MJ. Electrocardiographic T wave abnormalities and the risk of sudden cardiac death: the Finnish perspective. Ann Noninvasive Electrocardiol. 2015;20:526–33.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.